Bevacizumab in newly diagnosed ovarian cancer

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages 876-878

  Liu, Joyce F ^a   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; HIGH RISK POPULATION; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NOTE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; FEMALE; OVARIAN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84938207700     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00064-9     Document Type: Note

References (10)

1. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015, published online June 23. http://dx.doi.org/10.1016/S1470-2045(15)00086-8.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
3. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
4. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
5. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32:1302-1308.
6. Coleman R, Burger RA, Brady MF, et al. Analysis of survivorship in high-risk patients on treated on GOG-218. Gynecol Oncol 2013, 130:e112-e113.
7. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013, 14:1020-1026.
8. Chan J, Brady MF, Penson RT, et al. Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). Int J Gynecol Cancer 2013, 23(8 suppl 1):9-10.
9. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015, published online May 19. http://dx.doi.org/10.1016/S0140-6736(14)62223-6.
10. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363:943-953.